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Abstract 
Background: Regeneration of new myelin is impaired in persistent multiple sclerosis (MS) lesions, leaving neurons 
unable to function properly and subject to further degeneration. Current MS therapies attempt to ameliorate auto‑
immune‑mediated demyelination, but none directly promote the regeneration of lost and damaged myelin of the 
central nervous system (CNS). Development of new drugs that stimulate remyelination has been hampered by the 
inability to evaluate axonal myelination in a rapid CNS culture system.
Results: We established a high throughput cell‑based assay to identify compounds that promote myelination. 
Culture methods were developed for initiating myelination in vitro using primary embryonic rat cortical cells. We 
developed an immunofluorescent phenotypic image analysis method to quantify the morphological alignment of 
myelin characteristic of the initiation of myelination. Using γ‑secretase inhibitors as promoters of myelination, the 
optimal growth, time course and compound treatment conditions were established in a 96 well plate format. We 
have characterized the cortical myelination assay by evaluating the cellular composition of the cultures and expres‑
sion of markers of differentiation over the time course of the assay. We have validated the assay scalability and consist‑
ency by screening the NIH clinical collection library of 727 compounds and identified ten compounds that promote 
myelination. Half maximal effective concentration (EC50) values for these compounds were determined to rank them 
according to potency.
Conclusions: We have designed the first high capacity in vitro assay that assesses myelination of live axons. This 
assay will be ideal for screening large compound libraries to identify new drugs that stimulate myelination. Identifica‑
tion of agents capable of promoting the myelination of axons will likely lead to the development of new therapeutics 
for MS patients.
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Background
Multiple sclerosis (MS) is the most common disabling 
neurological disease of young adults; once established, it 
persists for the remainder of a person’s life [1]. The ini-
tial triggering events which lead to MS remain unknown 
and there is no cure. In MS, central nervous system 
(CNS) lesions form as a result of immune-mediated 
destruction of myelin sheaths that insulate and protect 
axons, resulting in loss of function and, ultimately, pro-
gressive neurodegeneration and permanent neurologi-
cal decline. Current MS therapeutics mainly target the 
autoimmune response that damages myelin sheaths. 
Although effective in reducing relapses in early disease, 
none of them prevent long-term disease progression and 
none are effective in treating progressive forms of MS. 
A major unmet medical need in MS is the availability 
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of therapeutics that directly protect myelin or promote 
new myelin formation to maintain nerve function, pre-
vent neurodegeneration, and restore lost function in MS 
patients.
A key deficit in the development of myelin repair 
therapeutics is the lack of a high throughput axonal 
myelination assay suitable for drug discovery. The closest 
available high throughput systems assess differentiation 
of purified oligodendrocyte precursor cells (OPC) or 
oligodendrocyte (OL) wrapping of inert, non-biological 
substrates, neither of which incorporate the complex 
cellular interactions between OPC/OLs and live axons 
[2–4]. Existing myelination assays are very low through-
put, time consuming, and are designed for exploring 
basic research themes rather than to drive drug develop-
ment decisions. Development of an assay that evaluates 
axonal myelination, incorporates the complete reper-
toire of CNS cells, and can be performed at a scale and 
reproducibility that permits testing large numbers of 
potential drugs would provide a major advance in the 
efforts to develop remyelination-promoting therapeutics 
for MS patients. We describe here the development of 
such an assay and utilize it to identify potential myelin 
repair therapeutics.
In an effort to create a myelination assay more ame-
nable to higher throughput compound screening, we 
used embryonic rat cortex to develop, optimize, and 
validate an in vitro myelination assay [5, 6] which can 
be utilized for chemical library screening. The culture 
system was miniaturized into a 96-well plate format 
enabling high throughput liquid handling, automated 
image acquisition and analysis of myelinating co-cul-
tures. It has previously been shown that inhibition of 
the γ-secretase protease activity promotes differen-
tiation of OPCs and myelination of retinal ganglion 
cells (RGC) in RGC-OPC co-cultures [7–9]. Based on 
this published work, we used the γ-secretase inhibitor 
(GSI), N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phe-
nylglycine t-butyl ester (DAPT) as a positive control 
in our cortical co-cultures [9], and confirmed that the 
assay allows for the quantification of early axonal mye-
lination in a dose-dependent manner. This assay identi-
fies compounds which are not active in a pure primary 
OPC differentiation assay [3, 10] but are capable of pro-
moting re-myelination in vivo [11]. We have used this 
myelination assay to screen the NIH clinical collection 
library of small molecules. Because this mixed CNS cell 
assay platform more closely mimics the complex cellu-
lar interactions in the CNS in vivo, it will also likely be 
scalable and adaptable to the high throughput screen-
ing of other neurological disease therapeutics in future 
studies.
Results
Development of the embryonic cortical cell co‑culture 
assay
In an effort to move a low-throughput, well-established 
myelination cell culture technique to a format suitable 
for higher throughput screening applications, we minia-
turized and automated a previously described RGC-OPC 
co-culture technique [9]. Unfortunately, the low yield of 
RGCs and lack of assay robustness from each prepara-
tion makes this co-culture myelination assay unsuited for 
high-throughput compound screening (Additional file 1: 
Fig. S1A). We therefore sought another source of tissue 
where numbers of neurons would not be limiting.
For increased yield of primary neurons, we chose the 
cortex of embryonic day 18 (E18) rats as an abundant 
source of relatively homogeneous brain cells with well-
established culture methods [5, 6] (see “Methods”). From 
one litter, enough cells can easily be generated for high 
throughput drug screening applications (~30 × 106 cells/
cortex; Additional file 1: Fig. S1B).
Following the differentiation and growth of neurons 
and glia for 5 days, we determined that the differentiation 
and early myelination of exogenously added OPCs pro-
ceeded optimally when the growth medium was switched 
from NB/N21 to an OPC-supporting myelination 
medium (MyM). With this growth medium, we observed 
that it was not necessary to add exogenous OPCs as we 
could readily identify mature and axon ensheathing OLs 
that had differentiated from the embryonic cortical prep-
aration, presumably from neural precursor cells and/or 
OPCs. We actually found that the differentiating OPCs 
already present in the cultures produced better myelina-
tion (Additional file 2: Fig. S2, see below and methods for 
quantification of myelination). Finally, we determined 
that the optimal time course for myelination to proceed 
was 8  days after test compound addition and 13 DIV 
total (Additional file 3: Fig. S3). Figure 1 depicts the flow 
scheme of the embryonic cortical cell assay. At this early 
myelination time point, we observed MBP staining align-
ing with SMI 31/32 axon staining, indicating that indeed 
OLs are contacting and aligning with axons (Fig. 2a).
We utilized the γ-secretase inhibitor, DAPT, a known 
enhancer of myelination [9, 11] as a positive control to 
test our assay system and establish an automated mor-
phology analysis. After compound treatment, cells were 
stained for the OL lineage marker, Olig2, myelin basic 
protein (MBP) to stain mature OLs, and the nuclear dye, 
DAPI, and imaged. Myelination was scored by quanti-
fying the characteristic change of morphology of OLs 
when ensheathing axons—from many branched, flat-
tened, and diffusely MBP stained processes to con-
densed and aligned MBP-positive fibers. For each high 
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resolution 10× image, we quantified the total length of 
contiguous, aligned MBP staining (fiber length)/number 
of Olig2-positive (Olig2+) nuclei, referred to as myeli-
nation). Figure  2b demonstrates the digital mask cre-
ated by our protocol used in the fiber length calculation. 
With these methods, we determined significant dose-
dependent increases in myelination with DAPT (Fig. 2c). 
Importantly, we were able to determine reproducible 
EC50 values of four GSI compounds, DAPT, LY411,575, 
BMS 708,163, and MRK560, allowing the ranking of 
compounds (Fig.  3a–d, Table  1). GSI-mediated facilita-
tion of myelination was only observed in the presence 
of live axons and had no effect on the differentiation of 
purified OPCs grown in isolation (Additional file 4: Fig. 
S4). We tested two other compounds identified from 
published high throughput library screens that promote 
OL differentiation in cultures containing purified OPCs, 
benztropine and clemastine [2, 3]. As expected, these 
compounds demonstrated significant OL differentiation 
in our acutely prepared OL differentiation assay (Addi-
tional file  4: Fig. S4). However, in our cortical myelina-
tion assay, benztropine and clemastine did not promote 
myelination (Additional file 5: Fig. S5). This data demon-
strates that the cortical myelination assay identifies novel 
compounds with myelination activity distinct from com-
pounds that solely promote OL differentiation.
Long‑term characterization of cortical myelination cultures
To test whether the enhanced early myelination effects 
of GSIs had longer lasting effects with the single 8  day 
drug treatment course, cortical cultures were treated as 
described followed by 2  weeks of half medium changes 
with fresh MyM without GSI compound. These GSI-
treated cultures demonstrated robust MBP alignment 
compared to DMSO vehicle controls (Fig.  4a, b). Addi-
tionally, we tested these cortical cultures for their abil-
ity to initiate the formation of axonal nodes of Ranvier, 
essential to action potential propagation in functionally 
myelinated axons. As an indicator of early node forma-
tion, we immunostained these longer term cultures with 
antibodies to the paranode-localized protein, Caspr [12] 
along with anti-MBP antibodies. Figure 4c demonstrates 
the accumulation of Caspr protein at the edges of mye-
linated axon segments indicating that the initiation of 
node formation was induced by contact with OL myelin. 
These data demonstrate the ability of cortical cultures 
to form robustly myelinated axon segments and initi-
ate node formation which is enhanced by an early, single 
dose treatment with GSIs.
Cellular composition of cortical myelination cultures
To determine the composition of these cortical cultures, 
we used well-established cell type marker antibodies to 
identify different cell populations. Cultures were grown 
using the culture conditions described above, and fixed 
on DIV13. All cultures were stained with the nuclear 
marker DAPI to identify the total population of all the 
cells in culture. To identify the neuronal population, we 
used anti-NeuN antibodies to identify neuronal nuclei, 
as well as anti-MAP2 and anti-SMI 31/32 neurofilament 
antibodies to assess the health and extent of dendrite 
and axon formation, respectively. Imaging of neurons 
in these cultures demonstrated mature cortical neurons 
with well-developed dendrites and a dense bed of axons 
(Additional file  6: Fig. S6). In addition to NeuN for the 
identification of neurons, we also used anti-Olig2 anti-
bodies to identify OPC/OLs and anti-GFAP antibodies to 
identify astrocytes. We then quantified the percentage of 
each of these cell types in this cortical co-culture prepa-
ration as a percentage of the total cell population identi-
fied with DAPI nuclear staining of all cells. We found that 
the cell composition under these culture conditions was 
23 % neurons, 46 % astrocytes, 22 % OPCs/OLs, and 9 % 
unidentified cells.
Fig. 1 Flow scheme for the cortical cell myelination assay. a Dissociated cells from the cortex containing neurons and glial progenitor cells were 
cultured from E18 rat embryos onto poly‑d‑lysine/laminin coated 96‑well plates. b On DIV4, when axonal projections (red) are apparent in the neu‑
ronal population, the growing co‑culture was changed to MyM media to induce OL differentiation and initiate myelination. The following day test 
compounds were added and cultures were left undisturbed for an additional 8 days. c Cells were fixed and immunostained for MBP, Olig2 and DAPI 
on DIV13. Images were acquired using automated microscopy and scored phenotypically for myelination as described in the “Methods”
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In order to better understand how OLs differentiate 
and develop in these cultures, we stained and imaged 
DIV5 cultures to assess the cell composition of our cul-
tures on the day of test compound addition. At this stage, 
the cultures contained ~50  % neurons, having already 
generated an axon network (Additional file  7: Fig. S7). 
Since our cultures were derived from embryonic cor-
tex, we used the bi-potent O2A glial progenitor anti-
body marker A2B5 [13, 14], to identify glial progenitors 
still capable of differentiating. DIV5 cultures contained 
abundant A2B5 positive cells which were not observed 
at DIV13 (Additional file 8: Fig. S8). There were relatively 
Fig. 2 Oligodendrocyte processes align with cortical axons and γ‑secretase inhibitors (GSIs) facilitate myelination. Cortical co‑cultures were treated 
with the GSI, DAPT or DMSO as described in Fig. 1. a On 13 DIV, cells were fixed and stained with antibodies to the axon marker SMI 31/32 neurofila‑
ment protein (red) and MBP (green). Image at the right is a composite of the SMI 31/32, MBP, and DAPI. Arrowheads indicate regions of MBP align‑
ment with axon. Bar 100 µm. b Left two panels show entire image fields taken from a 96‑well plate immunostained for Olig2 and MBP. Bars 200 µm. 
Boxed regions are enlarged in the middle panel to show morphological detail of MBP‑stained OLs. Bar 50 µm. Two images at right depict the digital 
mask of MBP staining intensity of the adjacent image (middle panel) and the far right image are tracings of MBP alignment used to calculate fiber 
length. Bars 50 µm. c Raw data from three DAPT dose response experiments was quantified from images as in b and compiled from n = 3 experi‑
ments, 80 image fields per concentration, mean ± SEM. Asterisk (*) denotes P values versus DMSO of <0.0001; ANOVA with Bonferroni post hoc test. 
There was a significant effect of four compound concentrations compared to DMSO [F(9, 19) = 83.82, P < 0.0001]. Post hoc comparisons indicated 
that the mean score for the concentrations 0.37 μM (M = 21.32, SEM = 1.3), 1.11 μM (M = 27.88, SEM = 1.9), 3.33 μM (M = 33.51, SEM = 1.9), 10 μM 
(M = 37.1, SEM = 2.5) was significantly different than DMSO
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few astrocytes (positively staining for GFAP) and dif-
ferentiated OLs (positively staining for MBP, CNP, O4 
or MOG) at this stage, indicating that a majority of the 
OL differentiation and myelination occurred during the 
test compound treatment window (Additional file 9: Fig. 
S9). Using the microglial marker Iba1, we detected <1 % 
microglial cells at DIV5, and undetectable microglia at 
DIV13.
NIH clinical collection library screening for compounds 
that promote myelination
To demonstrate that the assay conditions we developed 
were robust enough to support drug discovery screen-
ing efforts, we screened a small library of compounds. 
We selected the NIH Clinical Collection (NCC) library 
for screening which contains Food and Drug Adminis-
tration (FDA)-approved off-patent drugs. Therefore, 
hits retrieved from this collection could lead to poten-
tial drug candidates for further development and rapid 
Fig. 3 Half maximal effective concentration determination of four different GSIs for the promotion of myelination in the cortical culture assay. Dose 
response data confirm the activity of GSIs and enable the calculation of the EC50 value for each compound. Cortical cultures were treated for 8 days 
with DAPT, LY 411,575, BMS 708,163 or MRK 560 and immunostained for MBP, Olig2 and DAPI. Dose–response curve for DAPT is compiled from 
n = 3 experiments, 80 image fields per concentration. Representative dose–response curves for LY 411,575, BMS 708,163 and MRK 560 are 32 image 
fields per concentration, mean ± SEM. Respective EC50 values are shown in the legend
Table 1 Confirmed hits from the NCC library screen
a Compounds not part of the NCC library screen
b N = ≥ 2
Known mechanism of action Compound EC50 μM
b
avg
Kinase inhibitor Imatinib mesylate 1.4
Anti‑cholinergic Atracurium Besylate 5.3




Ion channels Zu‑capsaicin 4.7
Amiloride 8.9
Oxcarbazepine 14.7
Na2+/K+ ATPase inhibitor Digoxin 11.3
γ‑secretase inhibitors LY 411, 575a 0.00053
BMS 708, 163a 0.067
MRK 560a 0.082
DAPTa 0.55
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repositioning as therapeutics for MS. The NCC library 
consists of 727 biologically active compounds that have 
been through phase I–III clinical trials. This collec-
tion is additionally attractive because of the wide vari-
ety of cellular targets that are represented. Because this 
focused FDA-approved compound collection is small 
and the drug structures diverse, we decided to screen at 
two concentrations (5 and 1 μM) to reduce the possibil-
ity of missing hits due to false negatives. Each plate con-
tained eight wells treated with DMSO or DAPT controls 
and each test compound concentration was screened in 
duplicate.
Fig. 4 Long term cortical cultures demonstrate persistent GSI‑induced enhancement of myelination and initiation of axonal node of Ranvier forma‑
tion. On DIV5, cortical cultures were treated with DAPT or DMSO for 8 days, media was changed weekly thereafter without compound, and cells 
fixed on DIV28. a Left panels show triple immunostaining of MBP (green), Olig2 (red), and DAPI (blue). Red overlaid with blue appears pink. Right panels 
show digital masks created from MBP‑stained images in the center panel. Masks were used for quantification of fiber length. Bars 100 µm. Arrows 
indicate areas with significant myelination. b Quantification of myelination showing raw data in 28 DIV cortical cultures as in a. Representative data 
shown is averaged from 16 image fields per concentration, mean ± SEM. Asterisk (*) denotes P values versus DMSO of < 0.0001; ANOVA with Dun‑
nett’s post hoc test. There was a significant effect of three compound concentrations compared to DMSO [F(9, 27) = 17.50, P < 0.0001]. Post hoc 
comparisons indicated that the mean score for the concentrations 100 nM (M = 14.26, 2.433), 500 nM (M = 14.57, 2.32), and DAPT (M = 16.35, 1.39) 
was significantly different than DMSO. c Cortical co‑cultures were grown for a total of 21 days, fixed, and immunostained for MBP (green, merged 
image) and the paranode‑localized protein Caspr (red, merged image). Note the accumulation of Caspr protein at the edges of myelinated axon 
segments (arrows). Bar, upper panels 100 μm. Bar, lower panels 50 μm
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Automated image acquisition was performed from 
four randomized fields from each well, representing a 
total of eight data points per test concentration. The data 
was analyzed to find active compounds that increase 
myelin formation above a pre-defined threshold (>50 % 
of DAPT pro-myelinating activity). Though the thresh-
old is somewhat arbitrary, we included in our analysis 
the delineation of three SDs above the mean signal of 
DMSO-treated well (Fig.  5a). While not a criterion in 
our assay for hit selection, it provided a statistical assur-
ance that we were well out of a false-positive hit rate 
(0.15  %) range. Control DAPT versus DMSO values 
from the entire myelination screen were highly statisti-
cally significant (Fig. 5b) indicating an acceptable screen 
window.
We were concerned about the possibility of inter-
preparation variability and differences in the behaviors 
of dissociated primary neurons and glia in culture, so we 
considered how to evaluate the consistency of responses 
to treatment in addition to assessing the consistency of 
the plate controls. As a measure of assay quality, we con-
sidered the Z-factor; however, since our assay is based 
on multiple readouts, we incorporated an additional 
parameter for assay window and robustness, a specific 
morphological measurement of early myelination. This 
criterion is a quotient of two morphological measure-
ments—fiber length intensity score and MBP intensity 
score which adjusts for the contribution of OL differen-
tiation (MBP expression) (Additional file  10: Fig. S10). 
A ratio of one indicates that an observed increase in 
myelination may almost be entirely accounted for by an 
increase in the extent of OL differentiation, whereas a 
value significantly greater than one indicates that there 
is an observed increase in myelination above and beyond 
Fig. 5 Analysis of the cortical myelination screen of the NCC compound library. a High‑throughput screening data set used to identify promot‑
ers of myelination. The mean response is indicated by the solid line. The dotted line delineates the value of three SDs above the mean. Compounds 
that significantly reduced Olig2 expression were excluded. b High‑throughput screening data plate control values of myelination. Each point is an 
compiled control value from each screening plate (n = 44, 16 image fields per concentration, mean ± SEM *P < 0.0001, t test). c Using the fiber 
score/MBP score as a specific measure of myelination (see Additional file 10: Fig. S10), the ratio of the DAPT to DMSO controls demonstrates the 
screening assay window. The red line delineates the cutoff value of 1.3. Each point is an averaged value from each screening plate (32 image fields 
per condition, mean ± SEM). The average DAPT/DMSO‑fiber score/MBP score for the entire NCC library screen = 1.61 (dashed line). d NCC library 
hit selection process in the cortical culture myelination assay. Fifty‑three primary hits compounds were initially identified from the NCC library with 
the criteria of >50 % DAPT and >1.5 fiber score/MBP score or fiber/MBP. The primary hits were further refined with additional criteria of >25 % DAPT/
Olig2 nuclei ratio, <40 % DAPI/Olig2 nuclei ratio, and a visual morphology check to yield refined hits of 33 compounds. All refined hit compounds 
were reordered fresh and tested for efficacy in a dose–response profile. Ten compounds passed these criteria and were confirmed as hits
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what would be expected by an increase in OL differentia-
tion alone, i.e. specific induction of myelination. We pri-
marily used this to measure the quality of each plate in 
the screen. We typically observed DAPT treated cultures 
to have fiber score/MBP scores >1.5. Figure  5c depicts 
the DAPT/DMSO fiber score/MBP scores of each plate 
from the entire library screen which generated an aver-
age fiber score/MBP score of 1.61. For each plate in the 
screen, the acceptable fiber score/MBP score cutoff was 
in the range of 1.3 ± 0.2. In addition, the fiber score/MBP 
score was incorporated into the criteria for assay hits to 
potentially distinguish between active compounds with 
distinct mechanisms of action (see below). Additional 
file 12: Table S1 contains the data set for the entire library 
screen, showing the % DAPT normalized scores for mye-
lination for each library compound.
Selection criteria for myelination assay positive hit 
compounds
To select candidate compounds with substantial activity 
in our screen, compounds that had scores >50 % of DAPT 
were included as secondary hits (Fig.  5d). In addition, 
to further delineate the myelination effect enhanced by 
compounds, we implemented a second criterion of fiber 
score/MBP score (Additional file  10: Fig. S10) includ-
ing any compounds that had scores >1.5 (fiber score/
MBP scores for entire data set are included in Additional 
file 12: Table S1). Three compounds passed this criterion 
alone and were included in further hit compound refine-
ment. We observed that some compounds displayed 
unusually large myelination scores but had very low over-
all Olig2+ nuclei expression, which could either reflect 
an inhibition of OL proliferation or increased OL cell 
death (e.g. methotrexate, Additional file 11: Fig. S11B7). 
Not surprisingly, visual assessment of images from these 
cultures revealed a low overall number of myelinat-
ing OLs. We therefore incorporated a third criterion to 
eliminate compounds that primarily act as anti-prolifer-
ative compounds and thus greatly reduced Olig2 expres-
sion: the ratio of total nuclei (DAPI staining)/Olig2+ 
nuclei. Large DAPI/Olig2+ nuclei numbers (>40) were 
an indicator that the test compound severely depleted 
OPCs and OLs, undesirable in a screen for compounds 
that promote myelination. DAPT reduces the number of 
Olig2+ cells by ~50 %, most likely by promoting OPC dif-
ferentiation and reducing OPC proliferation [9]. There-
fore, we implemented a criterion of >25 % of the DAPT 
Olig2+ cell count which also effectively eliminated com-
pounds that severely reduced the number of Olig2+ cells 
(Fig.  5d). A fourth criterion was the qualitative assess-
ment of OL MBP staining, taking into account the num-
ber of OLs/image field and OL morphology. Compounds 
that dramatically changed OL morphology (e.g. greatly 
enlarging the cell) while reducing the number of OLs/
field were eliminated. Active compounds that passed all 
of these criteria were referred to as refined hits (Fig. 5d). 
A fifth criterion was to confirm activity and potency of 
refined hit compounds with full dose–response curve 
experiments of at least two replicates using reordered 
or resynthesized material. Actives that met this criterion 
were referred to as our confirmed hits (Fig. 5d) and our 
hit rate is based on this number. In a screen of 727 FDA-
approved drugs, our screen identified 53 primary hits, 
33 refined secondary hits and ten confirmed and repro-
ducible hits (Table 1). The resulting hit rate for the entire 
screen was ~1.7 %. Additional file 11: Figure S11 shows 
the chemical structure of each hit compound, screening 
image of MBP/Olig2/DAPI staining, and the EC50 curves 
for myelination. Table  1 shows the calculated myelina-
tion EC50 values for the top hits from our cortical myeli-
nation screen. Based on the available literature on these 
previously characterized compounds, we grouped the 
hits based on the known mechanisms of action. These 
compounds fell into many different classes, grouped in 
Table  1, and are distinct from compounds previously 
identified by other library screens that have used OL dif-
ferentiation assays in the absence of axons [2–4]. These 
data represent an initial screen to identify myelination-
promoting compounds. Future studies will include an 
investigation of compound mechanisms as well as a thor-
ough characterization of how these compounds effect 
cellular composition of the cultures.
Discussion
Development of high throughput cortical myelination 
assay
It has become clear that focusing solely on the immu-
nological component of MS only addresses one aspect 
of the disease. Repairing damaged myelin and/or pro-
moting the remyelination of demyelinated axons within 
lesions would, at a minimum, facilitate the preservation 
and/or restoration of some neuronal function. This may 
also prevent the irreversible neuronal damage believed to 
underlie the progressive disability that eventually affects 
most MS patients. Thus, remyelinating compounds are 
highly sought after, but have been difficult to identify in 
part because of the lack of HTS assays that truly detect 
myelination.
Our goal for developing a co-culture with live axons 
and oligodendrocytes as a myelinating in  vitro system 
was to overcome the challenges of labor intensive OPC/
neuron preparations, inconsistent performance of clas-
sical sources of neurons for modeling myelination (e.g. 
RGCs, dorsal root ganglion cells), and generating suffi-
cient quantities of cells required for a robust HTS assay. 
In this study, we have described the development of the 
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first in vitro myelination assay that assesses the functional 
dynamic interaction between live axons and oligoden-
drocytes during myelination and can be performed with 
a simple culture technique at a scale and reproducibility 
amenable to HTS drug discovery. This assay is unique in 
that it evaluates test compounds in the presence of the 
co-developing milieu of native brain cells, including OLs, 
neurons, and astrocytes. We demonstrate here that pri-
mary embryonic cortical tissue is an abundant cell source 
for both neurons and OPCs that are myelination compe-
tent [5, 6], easier to culture than RGCs, and widely used 
in large-scale HTS screening within the pharmaceuti-
cal industry. We have validated this assay using GSIs, 
establishing EC50 values for four different compounds to 
allow the ranking of potency. Using this assay as an initial 
screen, we screened the NCC library and identified ten 
confirmed hit compounds from diverse target classes for 
follow-up characterization.
Perhaps the most important aspects of the cortical 
myelination assay are that OLs develop and differenti-
ate alongside growing axons and astrocytes, two major 
sources of signaling molecules known to influence myeli-
nation. The expression of the axonal protein LRR and Ig 
domain-containing, Nogo receptor-interacting protein 
(LINGO-1) was demonstrated be a potent inhibitor of 
differentiation and myelination [15–17]. Indeed, anti-
LINGO-1 antibody is being developed as an MS thera-
peutic to promote axon remyelination and is currently in 
human clinical trials (BIIB033, ClinicalTrials.gov identi-
fiers: NCT01244139, NCT01052506, NCT01864148). 
Leukemia inhibitory factor (LIF) has been shown to be 
released by astrocytes in response to ATP from action 
potential firing axons to promote myelination [16]. Addi-
tionally, through the action of TNFR2 on astrocytes, 
LIF is produced to stimulate OL differentiation in a co-
culture system [18]. Furthermore, astrocytes were dem-
onstrated to reduce OL differentiation, but specifically 
enhance myelin thickness and the rate of axon wrapping 
[9]. TNF impairs OL differentiation [19] attenuating TNF 
signaling by TNFR1 blocking therapy ameliorates MS 
symptoms in EAE [20]. It was also demonstrated that 
inhibiting glial γ-secretase promoted myelination [9], 
which also showed efficacy in vivo in the EAE model of 
MS [11]. These observations emphasize the importance 
of having culture conditions that more closely mimic the 
in vivo CNS composition.
It is important to note that this cortical myelina-
tion assay may fail to identify all possible compounds 
that may promote myelination. Due to the relatively 
short time course and single compound addition, our 
assay may not identify compounds with short half-lives, 
require multiple target activations, or require longer time 
courses. The assay could be modified by spiking in test 
compounds during the course of the ensheathment win-
dow and/or lengthen the ensheathment window longer 
than 8 days. We included T3, forskolin, and CNTF in the 
MyM medium as factors that facilitate OL differentiation 
and survival [21]. The activity of these factors may mask 
effects of potential stimulators of myelination. In particu-
lar, elimination of T3, may lower the threshold for identi-
fying additional candidate compounds. This stimulation 
of differentiation by T3 may account for the lack of OL 
differentiation activity of benztropine and clemastine in 
our cortical myelination assay. Elimination of these fac-
tors from the myelination phase of the assay may reveal 
additional compounds with myelination activity.
The cortical myelination assay identifies compounds not 
revealed by OL differentiation assays
Our myelination assay greatly differs from in vitro OL dif-
ferentiation assays used for compound screening which 
have only assessed differentiation using purified OPCs (in 
isolation from axons and astrocytes) adapted to culture 
conditions by multiple passages [2, 3], or differentiated 
from induced pluripotent stem cells [22] and carried out 
in very short developmental time frames. Mei et al, 2014 
[2] developed an HTS assay incorporating OL differen-
tiation in the presence of inert micropillers allowing the 
quantification of pillar wrapping as a surrogate for myeli-
nation [2]. Lead compounds identified from these three 
studies, including clemastine, benztropine, miconazole 
and clobetasol, facilitate OL differentiation in cultures of 
purified OPCs [2–4] (Additional file 8: Fig. S8), but had 
no effect on myelination in our live axon myelination 
assay (Additional file 9: Fig. S9, Additional file 12: Table 
S1, compounds 450—clobetasol and 588—miconazole). 
Notably, our myelination assay did not identify mus-
carinic antagonists as previously identified by independ-
ent OL differentiation screens [2, 3], but revealed entirely 
new classes of compounds that promote myelination. 
No other high throughput assay has been developed to 
date capable of assessing the initiation and facilitation of 
myelination in the presence of axons, arguably the most 
important features when selecting candidate compounds 
capable of promoting or generating remyelination.
Relation of cortical myelination assay hit compounds 
to clinical applications and multiple sclerosis
Repositioning approved drugs for the treatment of new 
indications is an activity that has grown in popularity in 
recent years and is a trend that is predicted to continue. 
There are many examples where repurposed drugs are 
making an impact in the field of MS. A few to note are 
BG-12 (Tecfidera®), a modification of Fumaderm®, used 
to treat psoriasis; fingolimod (Gilenya®), originally devel-
oped for transplantation and alemtuzumab (Lemtrada™), 
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an oncology drug. We found that eight out of our ten 
confirmed hit compounds aligned with current MS repo-
sitioning efforts and are briefly cited here.
A treatment for congestive heart failure, digoxin (Lan-
oxin™) enhances both myelination and differentiation in 
our assay. It has been shown to reverse conduction block 
in demyelinated nerve fibers in experimental animals. 
Moreover, digoxin and possibly its derivatives, have also 
been implicated as a possible therapeutic for MS. A clini-
cal study involving MS patients, showed improvement of 
symptoms when given the drug intravenously [23].
Other hits have shown efficacy in MS animal mod-
els. Imatinib mesylate (Gleevec™), a kinase inhibitor 
used for cancer treatment, is efficacious in experimen-
tal autoimmune encephalomyelitis (EAE) models [24]. 
Artesunate, a natural compound used to treat malaria, 
has a derivative form (artemisimin) that has anti-
inflammatory properties in EAE [25]. Methotrexate 
(Trexall™), an anti-metabolite used to treat rheuma-
toid arthritis, is also efficacious at restoring myelin in 
cuprizone-induced demyelination mouse models [26]. 
In addition, methotrexate is commonly used off-label 
in MS, and is suggested as a low-dose, add-on therapy 
in combination with other treatments, to reduce the 
relapsing-remitting rate in MS [27] and to slow the pro-
gression of MS.
Some hits have been evaluated or will soon be tested in 
human MS patients. Oxcarbazepine (Trileptal®), a treat-
ment for seizures and amilioride (Midamor®), a treat-
ment for high blood pressure, have been demonstrated 
to be neuroprotective in rodent models of MS and in 
MS patients [28], and are now in human clinical trials to 
treat progressive MS (PROXIMUS Trial NCT02104661; 
MS-SMART Trial NCT01910259). Additionally, there is 
a patent for docetaxel (Taxotere®), an anti-microtubule 
and treatment for cancer (US6515016B2) on its use to 
treat or prevent psoriasis and MS.
Off-label muscle relaxants are used, when necessary, 
to help MS patients offset or reduce relapsing-remitting 
episodes. Atracurium besylate (Tracrium™) is used as an 
adjunct to general anesthesia and particularly useful for 
MS patients undergoing surgery since general anesthesia 
can exacerbate MS symptoms. In a clinical case report, a 
patient with MS underwent surgery for renal failure, and in 
a 3 month follow-up, reported no further MS attacks [29].
The remainder of our confirmed hits, zu-capsaicin 
(Civanex™) and tegafur (Uftoral®) have not been tested in 
any demyelinating diseases.
To our knowledge the myelin restorative effects of these 
compounds have not been evaluated. Our data suggests 
that these drugs should additionally focus on testing these 
hits to determine whether they have beneficial effects on 
remyelination in vivo and possibly in MS patients.
Conclusion
We have developed the first high capacity, phenotypic 
in  vitro assay amenable to high throughput screening 
to identify compounds that promote myelination. Our 
myelination assay incorporates both live axons and 
astrocytes, both of which have profound effects on mye-
lination in vivo. Our assay utilizes primary cortical cells 
under conditions that allows for endogenous myelina-
tion, and thus avoids potential artefacts due to the use 
of cell lines or artificial substrates for myelination. To 
demonstrate the utility of this assay, we have screened 
the NCC library of FDA-approved compounds, iden-
tifying ten compounds for follow up studies, including 
effects on different cell types, mechanisms of action, 
structure–activity relationship determination, and in 
in  vivo models of MS. Our hope is that this cortical 
myelination assay will be scaled up to screen even larger 




Dulbecco’s modified Eagle Medium (DMEM) high 
glucose, Neurobasal medium (NB), Hank’s balanced 
Salt Solution (HBSS), Earle’s balanced Salt Solution, 
l-glutamine, sodium pyruvate, penicillin/streptomy-
cin, Diamidino-2-Phenylindole, Dilactate (DAPI) were 
purchased from Life Technologies (Carlsbad, CA, 
USA), N21-MAX medium supplement from R&D Sys-
tems (Minneapolis, MN, USA), normal goat and fetal 
bovine serum, forskolin, triiodothyronine (T3), vitamin 
B12, hydrocortisone, biotin, boric acid, apotransfer-
rin, putrescine, progesterone, sodium selenite, poly-
d-lysine, recombinant human insulin, bovine serum 
albumin and DMSO were obtained from Sigma-Aldrich 
(St. Louis, MO, USA). Trace elements B and trypsin 
0.05  %-EDTA were purchased from Mediatech, Inc. 
(Manassas, VA, USA). Human ceruloplasmin was pur-
chased from EMD Millipore (Billerica, MA, USA). 
Recombinant human BDNF and CNTF were pur-
chased from PeproTech (Rock Hill, NJ, USA). Laminin 
was obtained from Trevigen (Gaithersburg, MD, USA). 
DNase and papain were purchased from Worthington 
Biochemical Corporation (Lakewood, NJ, USA). Pack-
ard Viewplates 96-well were purchased from Perkin 
Elmer (Waltham, MA, USA). Additional file  13: Table 
S2 lists the primary antibodies and their dilutions used 
in this study.
Cell culture methods
All animal work was carried out in strict accordance 
with the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the National Institutes of 
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Health. All animal protocols were approved by Institu-
tional Animal Care and Use Committee (IACUC) at the 
Molecular Medicine Research Institute. Animals were 
either euthanized by CO2 asphyxiation or decapitation.
RGC‑OPC culture methods
RGCs were prepared from P6-P7 Sprague–Dawley rat 
pups (Charles River, Wilmington, MA, USA), follow-
ing the RGC immunopanning purification protocol as 
described in Watkins et al. [9]. On DIV11 of RGC culture, 
cortical OPCs were purified from P7 Sprague–Dawley rat 
pups, following the OPC immunopanning purification 
protocol (as described in [30]). Six days following test 
compound addition (17 DIV), cells were fixed, immu-
nostained and imaged as described below.
Embryonic cortical culture methods
The dissection of E18 rat (Charles River, Wilmington, 
MA, USA) cortex is similar to that described previ-
ously [31–33] with some modifications. Briefly whole 
cortices from three embryos were collected in a petri 
dish containing HBSS. After carefully removing the 
meninges, the tissue was divided into cortical hemi-
spheres, dissected and the non-cortical structures were 
removed. Cortical tissue was then digested in 7  U/ml 
papain dissolved in HBSS with 500 U/ml DNase I, and 
incubated for 30 min at 35 °C. The enzymatic reaction 
was terminated with DMEM containing 10 % FBS. The 
tissue was allowed to settle, supernatant was removed 
and tissue was triturated with a flame-polished glass 
Pasteur pipette in DMEM/10 % FBS, 250 U/ml DNAse 
I until the tissue was completely dispersed. The dissoci-
ated cell suspension was centrifuged at 200×g for 5 min 
and supernatant replaced with plating medium (NB 
medium with 1× N21 supplement and 2  mM  l-glu-
tamine and 1  % penicillin–streptomycin). Viable cells 
were counted using trypan blue exclusion and typi-
cally exceeded 80  %. Isolated cells were seeded onto 
96-well plates pre-coated with poly-d-lysine (10  μg/
ml) and laminin (2 μg/ml) at a density of 20,000 cells/
well (2  ×  105 cell/cm3). Neurons were allowed to 
adhere, recover, mature and extend axons for 3  days. 
On the fourth day, the plating medium was diluted 
with an equivolume of myelination medium (MyM), 
as described in Watkins et  al. [9] with minor modifi-
cations (see “Results”). The following day, two-thirds 
of the medium was replaced with fresh MyM and test 
compound. The day after establishing the primary cul-
ture was defined as day 1 in vitro (DIV1).
Acute oligodendrocyte differentiation assay
OPCs from P7 Sprague–Dawley rat pups were purified 
by immunopanning and cultured as described [30]. OPCs 
were plated at 5000 cells/well into pDL-Laminin coated 
96-well TC plate wells and centrifuged at 200×g to facili-
tate cell attachment, survival, and assure even distribu-
tion of OPCs. Plated OPCs were pre-incubated for 1–2 h 
at 37  °C in 10  % CO2 incubator, followed by addition of 
test compounds in quadruplicate. Controls were added in 
eight replicate wells, negative control = 0.1 % DMSO final 
concentration; positive control = 40 ng/ml T3. The day of 
OPC plating was considered DIV0. On DIV4, cells were 
fixed, immunostained, and imaged as described below. 
Minor modifications include blocking cells with 10  % 
normal goat serum (NGS)/0.4 % Triton X-100 and stain-
ing overnight at 4 °C with rat anti-MBP antibodies diluted 
in 10 % NGS/0.08 % Triton X-100. OL differentiation was 
quantified by IN Cell Developer Toolbox image analysis 
software which calculated the MBP staining intensity of 
two images per well. The extent of OL differentiation was 
defined by the total threshold-selected area of MBP stain-
ing x MBP fluorescence intensity in this area divided by the 
total number of OLs (identified by DAPI nuclear staining).
Immunofluorescence staining and imaging
At the experimental end point, medium was removed 
leaving 50  μl/well using an ELX405 microplate washer 
(BioTek, Winooski, VT, USA). Cells were then fixed for 
14  min with paraformaldehyde solution to a final con-
centration of 4 %. Following fixation, plates were washed 
with 1  ml PBS leaving 50  μl/well using the microplate 
washer. Cells were then blocked in blocking buffer 
(10  % normal goat serum, 0.1  % Triton X-100), anti-
body buffer (150 mM NaCl, 50 mM Tris Base, 1 % BSA, 
100  mM  l-lysine, 0.004  % sodium azide, pH 7.4), and 
stained with mouse anti-rat MBP antibody and anti-
rabbit Olig2 diluted in blocking buffer overnight at 4 °C. 
The cells were washed and incubated with secondary 
antibodies, and DAPI, 0.3 μM for 1 h at room tempera-
ture. After a final wash, 100 μl of PBS was added to each 
well and plates imaged. Images were captured with a 
Nikon Eclipse TE-2000-U microscope, Zyla cMOS meg-
apixel camera (ANDOR Technology, Belfast, UK), fitted 
with an automated stage controlled by NIS Elements AR 
software 4.0 (Melville, NY, USA). An air 10X lens was 
used to capture four images per well with 16 bit resolu-
tion, 2560 × 2160 pixels. Images for each assay run were 
captured using identical camera settings. Images were 
exported as TIFF files for analysis and quantification.
Image quantification
TIFF files were analyzed using a custom algorithm cre-
ated with IN Cell Investigator Developer Toolbox (GE 
Health Sciences, Piscataway, NJ, USA). For each well, 
four images were analyzed and the data from the dupli-
cate well combined and averaged (total of eight images 
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per test condition). The extent of OL differentiation 
was defined by the total threshold-selected area of 
MBP staining × MBP fluorescence intensity in this area 
divided by the total number of OLs (identified by Olig2 
nuclear staining). We referred to this as the “MBP score” 
or “OL differentiation”. Earlier publications have char-
acterized in  vitro myelination as contiguous segments 
of MBP staining co-localizing with axons, representing 
the contact and ensheathment of axons with the myelin 
membrane generated by OLs. Hence, our assay defined 
myelination as the alignment of MBP staining assum-
ing the shape change into long straight contiguous seg-
ments. Our fiber length algorithm delineated only what 
it identified as continuous straight lines from an image 
field, and then applied morphometric quantification of 
intensity of those selected lines (calculates the total pixel 
length within a single fibrous shape). This value was then 
divided by the total number of OLs to give the value 
referred to as “fiber score” or “myelination”. The quotient 
of the myelination score and the MBP score equals a 
value we referred to as “fiber score/MBP score”, reflecting 
myelination independent of the effects of differentiation; 
in other words, MBP staining specific to myelination. 
Numerical results from the analyzed images were later 
exported for analysis in Microsoft Excel (Redmond, WA, 
USA). Data was normalized by fitting parameters to posi-
tive (1 μM DAPT) and negative controls (0.1 % DMSO) 
and expressed as the % of DAPT.
Relative EC50 analysis
Half maximal effect concentrations (EC50) values were 
obtained by fitting the data to a sigmoidal dose–response 
curve-fitting function (Prism, GraphPad software, La 
Jolla, CA, USA). Serial dilutions of eight to ten different 
concentrations with four data points per concentration 
were used for curve fitting. Experiments were repeated at 
least two times.
Compounds
All compounds in the NCC library were supplied in 
DMSO at 10  mM in 96-well plates. Hit compounds 
were purchased as powders and stocks dissolved in 
DMSO to 10  mM for in  vitro studies (see Additional 
file  13: Table S2 for complete listing of compounds). 
N-[N-(3,5-Difluorophenacetyl)-l-alanyl]-S-phenylgly-
cine t-butyl ester (DAPT), LY411,575, and BMS 708163 
were from Selleckchem, MRK560 was purchased from 
Tocris.
Statistical methods
For all experiments, assuming normal distribution, two-
tailed t-tests were used to evaluate comparisons between 
two groups and ANOVA was used when more than 
two groups were compared. For the quantitative analy-
sis of in  vitro myelination and differentiation, a one-way 
ANOVA was conducted to compare the effect of each dose 
of compound with DMSO (Prism, GraphPad software, La 
Jolla, CA, USA). This was followed by post hoc compari-
sons using Bonferroni or Dunnett Multiple comparison 
tests. Where possible, data were represented as the mean 
(M) ± standard error of the mean (SEM) or standard devi-
ation (SD) unless otherwise indicated in the figure legends.
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